Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
26.87
+0.53 (2.01%)
At close: Jun 26, 2026, 4:00 PM EDT
26.87
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:35 PM EDT
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Claire Mazumdar Clemon |
Contact Details
Address: 116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States | |
| Phone | 617 468 4219 |
| Website | bicara.com |
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002023658 |
| CUSIP Number | 055477103 |
| ISIN Number | US0554771032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | Chief Executive Officer and Director |
| Ryan Cohlhepp Pharm.D. | President, Chief Operating Officer and Director |
| Ivan Hyep M.B.A. | Chief Financial Officer and Treasurer |
| Rachel Frank | Vice President of Investor Relations and Corporate Communications |
| Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer and Corporate Secretary |
| Pauline Dufresne | Chief People Officer |
| Rachel Salazar | SVice President of Research & Development Strategy and Operations |
| Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations and Supply Chain |
| Angela Windt | Vice President and Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 144 | Filing |
| Jun 10, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| May 26, 2026 | 144 | Filing |
| May 21, 2026 | 8-K | Current Report |
| May 21, 2026 | 144 | Filing |
| May 18, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |